ReviewMedicina (Kaunas, Lithuania)2021
A 2021 Update on the Use of Liraglutide in the Modern Treatment of 'Diabesity': A Narrative Review.
Review in Medicina (Kaunas, Lithuania), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 42 citations in OpenAlex.
- Effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on abdominal fat distribution in people with obesity and type 2 diabetes mellitus evaluated by the energy spectrum ct: A prospective randomized controlled study.Frontiers in endocrinology · 2022Trial
- [Biophysical and biochemical differences in CADIMSS patients: Different therapeutic managements].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- The efficacy and safety of novel antidiabetic agents in polycystic ovary syndrome: a network meta-analysis.Journal of ovarian research · 2026Article
- Incretins (GLP-1 Receptor Agonists) and Polycystic Ovaries.JBRA assisted reproduction · 2025Review
- Obesity as a Part of Polycysric Ovary Syndrome (PCOS)-A Review of Pathophysiology and Comprehensive Therapeutic Strategies.Journal of clinical medicine · 2025Review
- Metabolic resilience: liraglutide's potential in alleviating depressive symptoms.Molecular biology reports · 2025Review
- Article
- Review
- A Combined GLP-1/PPARa/CB1-Based Therapy to Restore the Central and Peripheral Metabolic Dysregulation Induced by a High-Fructose High-Fat Diet.International journal of molecular sciences · 2025Article
- Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis.Journal of clinical medicine · 2025Article
- Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective.Journal of clinical and translational hepatology · 2025Review
- The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects.Journal of clinical medicine · 2024Review
- Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2024 · on this mapReview
- Liraglutide Protects Cardiomyocytes against Isoprenaline-Induced Apoptosis in Experimental Takotsubo Syndrome.Biomedicines · 2024Article
- An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database.Biomedicines · 2024Article
- Satiety: a gut-brain-relationship.The journal of physiological sciences : JPS · 2024Review
- Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?Journal of endocrinological investigation · 2023Review
- Microbiota-gut-brain axis: relationships among the vagus nerve, gut microbiota, obesity, and diabetes.Acta diabetologica · 2023Review
- Liraglutide inhibits AngII-induced cardiac fibroblast proliferation and ECM deposition through regulating miR-21/PTEN/PI3K pathway.Cell and tissue banking · 2023Article
- In Silico identification of novel phytochemicals that target SFRP4: An early biomarker of diabesity.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and type 2 diabetes mellitus have become a significant public health problem in the past decades. Their prevalence is increasing worldwide each year, greatly impacting the economic and personal aspects, mainly because they frequently coexist, where the term "diabesity" may be used. The drug class of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is one of the most modern therapy options in managing these metabolic disorders. This review focuses on the effects of liraglutide, a long-acting GLP-1 RA, in diabesity and non-diabetic excess weight. This drug class improves glycemic control by enhancing insulin secretion from the beta-pancreatic cells and inhibiting glucagon release. Furthermore, other effects include slowing gastric emptying, increasing postprandial satiety, and reducing the appetite and food consumption by influencing the central nervous system, with weight reduction effects. It also reduces cardiovascular events and has positive effects on blood pressure and lipid profile. A lower-dose liraglutide (1.2 or 1.8 mg/day) is used in patients with diabetes, while the higher dose (3.0 mg/day) is approved as an anti-obesity drug. In this review, we have summarized the role of liraglutide in clinical practice, highlighting its safety and efficacy as a glucose-lowering agent and a weight-reduction drug in patients with and without diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.